| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328088 | Acta Haematologica Polonica | 2015 | 7 Pages |
Abstract
Ruxolitinib is the first JAK kinase inhibitor registered for the treatment of primary myelofibrosis and post-polycythaemia vera myelofibrosis and post-essential thrombocytaemia myelofibrosis. The article is a summary of current clinical data with ruxolitinib therapy both in myelofibrosis and in other Ph-negative myeloproliferative neoplasms.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Tomasz Wróbel,